Exploring an Expanding AML Therapeutic Armamentarium: Expert Guidance to Optimize Outcomes
The goal of this activity is to improve the knowledge, confidence, and performance of learners to integrate recent findings into the treatment of patients with AML.
Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC
This program is intended for physicians, physician assistants, nurses, pharmacists, and other healthcare providers who care for patients with AML.
Upon completion of this activity, participants should be able to:
- Evaluate the clinical data on prognostic or predictive molecular features or aberrations in AML and describe their clinical importance in terms of diagnosis, risk prediction, assessment of measurable residual disease, and therapeutic decisions
- Plan evidence-based therapeutic strategies for older unfit patients, those with preexisting comorbidities, and/or those with secondary AML using novel targeted agents or formulations and refinements of conventional chemotherapy
- Develop personalized treatment plans for patients with newly diagnosed or relapsed/refractory AML with FLT3 or IDH1/2 mutations or positive for CD33
- Assess the available evidence to optimally integrate immunotherapeutic agents, including monoclonal antibody–based therapy, immune checkpoint inhibitors, vaccines, and adoptive cell–based therapy
- Address patient-specific challenges surrounding pre- and posttransplant processes and novel agents to mitigate risk
- Manage treatment-related toxicities associated with novel therapeutics
Daniel A. Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Division of Hematology
University of Colorado School of Medicine
Amir Fathi, MD
Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Eunice Wang, MD
Chief, Leukemia Service
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, New York
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest. In addition, all faculty presentations have been reviewed to ensure education is fair and balanced and that clinical content presented supports safe, effective patient care. Individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter.
NCCN continuing education considers financial relationships to create a conflict of interest when an individual has both a financial relationship with a commercial interest and the opportunity to affect continuing education content about the products or services of a commercial interest with which he/she has a financial relationship.
NCCN continuing education considers relevant financial relationships as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Amir T. Fathi, MD, has disclosed that he has received consulting fees from AbbVie, Agios, Astellas, Blueprint, Bristol-Myers Squibb, Foghorn, Genentech, Kite, Kura Oncology, Morphosys, Pfizer, Takeda, and Trillium and funds for research support from AbbVie, Agios, and Bristol-Myers Squibb.
Daniel A. Pollyea, MD, MS, has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene/Bristol-Myers Squibb, Genentech, Karyopharm, Kiadis, Novartis, Syndax, Syros, and Takeda and funds for research support from AbbVie.
Eunice S. Wang, MD, has disclosed that she has received consulting fees from AbbVie/Genentech, Astellas/Jazz, Bristol-Myers Squibb/Celgene/Kite, Gilead Sciences, GlaxoSmithKline, Kura Oncology, Mana, Novartis, Pfizer, Rafael, Stemline, and Takeda and non-CME/CE services from Dava Oncology, Kura, Pfizer, and Stemline.
The activity planning staff listed below discloses no relevant financial relationships:
CCO: Terrence Fagan; Megan Cartwright, PhD; Kristen Morrow; Timothy A. Quill, PhD; Jim Mortimer; June Wasserstrom; Kevin Obholz, PhD
NCCN: Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Kathy Ann Smith, CHCP
The NCCN clinical staff listed below discloses no relevant financial relationships:
Mallory Campbell, PhD
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.5 contact hours.
NCCN designates this application-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-21-093-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until July 8, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 1.50 AAPA Category 1 CME credit
- 1.50 ACPE contact hours
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC contact hours
- 1.50 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing